MedTrace Logo

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

NCT03298087 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-08-01

Study results available
· View outcomes & findings →

Summary

This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.

Conditions

  • Newly Diagnosed Oligometastatic Prostate Cancer

Interventions

PROCEDURE

radical prostatectomy

surgical removal of the prostate

RADIATION

stereotactic body radiotherapy

Highly targeted radiation

DRUG

Leuprolide

Lowers serum testosterone

DRUG

apalutamide

antiandrogen

DRUG

abiraterone

Inhibits androgen synthesis

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Nicholas George Nickols, MD PhD · VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2024-03-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03298087 on ClinicalTrials.gov